MaCH: Using sequence and genotype data to estimate haplotypes and unobserved genotypes by Li, Yun et al.
Genetic Epidemiology 34 : 816–834 (2010)
MaCH: Using Sequence and Genotype Data to Estimate Haplotypes
and Unobserved Genotypes
Yun Li,1 Cristen J. Willer,2 Jun Ding,2 Paul Scheet,3 and Gonc-alo R. Abecasis2
1Department of Genetics, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina
2Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan
3Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Genome-wide association studies (GWAS) can identify common alleles that contribute to complex disease susceptibility.
Despite the large number of SNPs assessed in each study, the effects of most common SNPs must be evaluated indirectly
using either genotyped markers or haplotypes thereof as proxies. We have previously implemented a computationally
efficient Markov Chain framework for genotype imputation and haplotyping in the freely available MaCH software
package. The approach describes sampled chromosomes as mosaics of each other and uses available genotype and shotgun
sequence data to estimate unobserved genotypes and haplotypes, together with useful measures of the quality of these
estimates. Our approach is already widely used to facilitate comparison of results across studies as well as meta-analyses of
GWAS. Here, we use simulations and experimental genotypes to evaluate its accuracy and utility, considering choices of
genotyping panels, reference panel configurations, and designs where genotyping is replaced with shotgun sequencing.
Importantly, we show that genotype imputation not only facilitates cross study analyses but also increases power of genetic
association studies. We show that genotype imputation of common variants using HapMap haplotypes as a reference is
very accurate using either genome-wide SNP data or smaller amounts of data typical in fine-mapping studies. Furthermore,
we show the approach is applicable in a variety of populations. Finally, we illustrate how association analyses of
unobserved variants will benefit from ongoing advances such as larger HapMap reference panels and whole genome
shotgun sequencing technologies. Genet. Epidemiol. 34:816–834, 2010. r 2010 Wiley-Liss, Inc.
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INTRODUCTION
Most ongoing genome-wide association studies (GWAS)
rely on a commercial SNP genotyping panel that directly
assays only a small fraction of SNPs in the human genome
[Carlson et al., 2003; The International HapMap Consortium
2005]. In these scans, the majority of SNPs in the genome
must be evaluated indirectly using one or more of the
genotyped SNPs as proxies [Barrett and Cardon, 2006; Pe’er
et al., 2006]. Despite the ability of individual genome-wide
association scans to identify common alleles that make large
contributions to disease risk and a subset of the loci with
smaller effect [Hirschhorn and Daly, 2005], many alleles
that contribute to complex disease can only be identified
through the meta-analysis of multiple genome-wide scans
[for specific examples, see Lettre et al., 2008; Sanna et al.,
2008; Willer et al., 2008, 2009]. Although it is possible to
assign SNPs genotyped in each study as proxies for SNPs
genotyped in the other studies [Carlson et al., 2004; de
Bakker et al., 2005; Lin et al., 2004; Nicolae, 2006; Zaitlen
et al., 2007], meta-analyses of GWAS conducted in this
manner would be cumbersome because of the limited
overlap between the different commercial panels and
because different choices of proxies for a particular SNP
might lead to somewhat different conclusions.
GENOTYPE IMPUTATION
A much more attractive approach for cross study
analyses is to combine genotypes generated by the
International HapMap Consortium, [The International
HapMap Consortium, 2005] with genotypes from indivi-
dual studies, and then use a haplotyping algorithm that
can handle genome scale data to impute genotypes at
untyped markers in each study [Scheet and Stephens,
2006]. This strategy results in a situation where all studies
are ‘‘genotyped’’ at all the markers examined by the
HapMap consortium (albeit some markers are genotyped
using conventional means and others are genotyped in
silico [Burdick et al., 2006]). The approach relies on the
intuition that even two apparently ‘‘unrelated’’ individuals
can share short stretches of haplotype inherited from
distant common ancestors. Once one of these stretches is
identified using genotypes for a few SNPs, alleles for
intervening SNPs that are measured in one of the
individuals, but not the other, can be imputed. Provided
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shared haplotype stretches are identified correctly, imputed
genotypes will be accurate unless they have been
disrupted by gene conversion or mutation events.
INITIAL EVALUATION OF IMPUTED
GENOTYPES AND HAPLOTYPES
Here, we systematically evaluate the genotype imputa-
tion approach outlined in the paragraph above using our
Markov Chain Haplotyping algorithm (MaCH 1.0; see
Appendix for implementation details). To estimate haplo-
types, our approach starts by randomly generating a pair
of haplotypes that is compatible with observed genotypes
for each sampled individual. These initial haplotype
estimates are then refined through a series of iterations.
In each iteration, a new pair of haplotypes is sampled for
each individual in turn using a Hidden Markov Model
(HMM) that describes the haplotype pair as an imperfect
mosaic of the other haplotypes. Model parameters that
characterize the probability of change in the mosaic
pattern between every pair of consecutive markers and
the probability of observing an imperfection in the mosaic
at each specific point are also updated. After many iterations
(typically 20–100), a consensus haplotype can be constructed
by merging the haplotypes sampled in each round.
HAPLOTYPING
Our approach was inspired by the Markov models
commonly used for pedigree analysis [for examples, see
Abecasis et al., 2002; Kruglyak et al., 1996; Lander and
Green, 1987] and shares several features with other HMMs
used to describe sampled haplotypes as a mosaic of a set of
reference haplotypes [Daly et al., 2001; Li and Stephens,
2003; Mott et al., 2000; Stephens and Scheet, 2005a]. In
order to evaluate its performance, we simulated two sets
of 100 1Mb regions that mimic the degree of linkage
disequilibrium (LD) in the HapMap CEU and YRI samples
[Schaffner et al., 2005]. In each region, we simulated
genotypes for 200 markers, ascertained to mimic
HapMap I allele frequency patterns [Marchini et al.,
2006], in 90 individuals with 2% of the genotypes missing
at random. We then used our method to reconstruct
individual haplotypes and tallied three measures of
haplotyping quality [Marchini et al., 2006]: (1) the number
of incorrectly imputed missing genotypes, (2) among
heterozygous sites, the number of consecutive sites that
are phased incorrectly with respect to each other (this is
the number of ‘‘flips’’ required to transform estimated
haplotypes into the true haplotypes, after masking
incorrectly imputed sites), and (3) the number of perfectly
inferred haplotypes. The three measures were averaged
over all 100 regions and the results are summarized in
Table I. For comparison, the table also includes results for
PHASE [Stephens and Scheet, 2005b; Stephens et al., 2001]
and fastPHASE [Scheet and Stephens, 2006], two state of
the art haplotyping algorithms [Marchini et al., 2006], and
for BEAGLE [Browning, 2006] and PL-EM [Qin et al.,
2002], two alternative haplotyping algorithms that are very
computationally efficient. Table I clearly shows that our
method is competitive in all three measures: our method
results in slightly fewer incorrectly imputed genotypes,
requires slightly fewer flips to transform imputed haplotypes
into the true haplotypes, and produces slightly more correctly
inferred haplotypes over the entire 1Mb stretch than PHASE,
which was the second best method. Furthermore, note that
estimates of haplotypes and missing genotypes obtained in
5–20min using our method are comparable in quality to
those produced by PHASE runs averaging 1 day.
GENOTYPE IMPUTATION FOR UNTYPED
MARKERS
Encouraged by these initial results, we proceeded to
apply our method to impute genotypes for untyped
markers in the Finland United States Investigation of
NIDDM genetics (FUSION) GWAS [Scott et al., 2007].
TABLE I. Quality of haplotypes and missing genotypes estimates
Dataset mimicking HapMap CEU Dataset mimicking HapMap YRI
Method ] Iterations Computation time ] Errors ] Flips ] Perfect ] Errors ] Flips ] Perfect
MaCH 20 2min 11.6 216 26.5 17.9 256 22.6
60 5min 10.8 200 28.4 16.6 232 24.1
200 15min 10.6 192 29.1 16.3 222 25.1
1,000 1.4 hr 10.6 182 29.3 16.3 218 25.5
3,000 3.9 hr 10.5 178 29.7 16.1 214 25.7
PHASE – 25 hr 12.6 201 25.3 19.8 270 19.9
fastPHASE – 17min 12.9 220 20.1 22.9 331 11.7
PL-EM – 3 sec 23.2 356 13.8 36.8 521 7.2
BEAGLE – 2 sec 13.9 230 21.1 23.1 332 13.1
The table summarizes results from the analysis of two sets of 100 simulated 1Mb regions. The two sets reflect the degree of LD in the
HapMap CEU and YRI samples, respectively. In each region, 200 markers were ascertained to mimic HapMap allele frequency spectra and
2%missing data was introduced at random. The data were then analyzed with one of five haplotypers (MaCH, PHASE, fastPHASE, PL-EM
and BEAGLE) and the quality of haplotype solutions and imputed genotypes evaluated. The number of missing genotypes imputed
incorrectly (] Errors), the number of switches in haplotype phase required to convert the estimated haplotypes into the simulated
haplotypes (] Flips) and the number of perfectly estimated haplotypes (] Perfect) was recorded. Averages of these three quantities are
tabulated. Mach 1.0 was run with default settings and different numbers of iterations. PHASE version 2.1.1 [Stephens and Scheet, 2005b;
Stephens et al., 2001] was run with default settings, as recommend by Matthew Stephens. fastPHASE version 1.3 [Scheet and Stephens,
2006] was run with default settings, as recommended by Paul Scheet. Beagle 2.1.3 was run with default settings, as recommend by Brian
Browning. PL-EM was run with settings recommended by Steve Qin. All timings refer to a 2.33GHz Pentium Xeon.
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Since a previous analysis suggested LD patterns in the
HapMap CEU and in FUSION are similar [Willer et al.,
2006], we used genotypes for 290,690 autosomal markers
with allele frequency 45% in the Illumina 317K SNP chip
and haplotypes for 2.5M polymorphic markers in the
phased HapMap CEU chromosomes as input. After
running the haplotyping procedure described above, we
estimated the most likely genotype at each position (taking
a majority vote across all iterations) and the expected
number of copies of the minor allele at each position (a
fractional value between 0 and 2) for each individual. We
obtained similar results running the haplotyping proce-
dure for 50–100 iterations or using only a smaller number
of iterations (10–20) to estimate model parameters and
then calculating maximum likelihood estimates for the
missing genotypes and allele counts. Different chromo-
somes were analyzed in parallel and, overall, imputing
genotypes for 2,335 unrelated individuals took o2 days
for each of the largest chromosomes on a 2006 vintage
2.40GHz Pentium Xeon processor. In total, we imputed
genotypes for 2,266,562 SNPs per individual. On average,
our method used stretches of 150 kb from the HapMap
CEU panel to reconstruct haplotypes for individuals in the
FUSION sample.
IMPUTATION IN THE FUSION
GENOMEWIDE ASSOCIATION
STUDY
To evaluate the quality of imputed genotypes, we
contrasted our estimates of the most likely genotypes
and the expected number of copies of the minor allele with
actual genotype data for three sets of markers: 521 SNP
markers in a region of chromosome 14 previously
examined to fine-map a candidate linkage region [Willer
et al., 2006], 1,234 SNP markers selected to augment
coverage of the Illumina 317K panel in regions surround-
ing 222 candidate genes [Gaulton et al., 2008] and 12,702
markers with MAFo5% not included in the set of 290,690
markers used for imputation. We expected the last two
panels of markers to be harder to impute, because they
represent SNPs that are not well tagged by the Illumina
317K SNP chip or that have lower MAF. We observed that
98.60% of imputed alleles matched actual genotyped
alleles in the fine-mapping panel, 96.24% in the candidate
gene panel, and 98.73% in the low MAF SNP panel.
Furthermore, the average r2 between imputed genotypes
and actual genotypes was 90.4, 79.1, and 74.0% in the three
SNP panels, respectively. This represents an improvement
of 14–39% compared to the best available single marker
tags, which provided an average r2 of 76.5, 52.8, and 35.5%
in the three SNP panels, respectively.
MEASURES OF IMPUTATION
QUALITY
Our Markov Chain produces three estimates of imputa-
tion quality and these can be used to focus analyses on
subsets of high-quality genotypes. First, it produces a
quality score that estimates the accuracy of each imputed
genotype and is simply the proportion of iterations where
the final imputed genotype (by taking a majority vote
across all iterations) was selected. Second, it produces an
overall measure of the accuracy of imputation for each
marker, which is the genotype quality score averaged
across all individuals. Finally, by comparing the distribu-
tion of sampled genotypes in each iteration with the
estimated allele counts that result from averaging over all
iterations, it produces an estimate of the r2 between
imputed and true genotypes (seeMethods for more details).
Quality measures for individual genotypes were good
predictors of imputation accuracy (Supplementary Figure 1,
Right Panel) and show that most imputed genotypes are
called with a high degree of confidence (Supplementary
Figure 1, Left Panel). For example, as measured by their
quality scores, the top 95% of genotypes had average
quality scores of 98.9% and actually matched experimental
genotypes 98.6% of the time. Most of the errors affect a
single allele so that, when measured on a per allele basis,
concordance increases to 99.3%.
To avoid preferential removal of rare genotypes or
alleles at each marker, we recommend using the per marker
quality scores to select a subset of imputed SNPs for
analysis, instead of the per genotype quality scores. Overall,
we saw a correlation of 0.77 between the estimated and
actual accuracy of imputed genotypes for each marker. We
also saw a correlation of 0.84 between the r2 estimated by
our method and the actual r2 that resulted from comparing
experimentally derived allele counts with their imputed
estimates. Figure 1 shows the ROC curve [Pepe, 2003] for
the two quality measures, showing that the estimated r2
measure is a more effective way to identify poorly
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Fig. 1. ROC curve comparing two measures of data quality. For
imputed SNPs on chromosome 14, where both imputed and actual
genotypes were available, we evaluated the ability of two different
measures of data quality (the estimated concordance between
imputed and true genotypes and the estimated r2 between imputed
and true genotypes) to discriminate between poor and well
imputed SNPs. Both estimates of imputation quality are calculated
without using the actual observed genotypes.
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imputed markers. In the FUSION GWAS scan [Scott et al.,
2007], we used an r2 threshold of 0.30 to decide which
markers were well imputed and should be included in
further analyses, and which were not. At this threshold,
we expect to remove 70% of poorly imputed markers
(those where r2 with experimental genotypes iso20%) but
only 0.50% of better imputed markers (those where r2 with
experimental genotypes is 450%).
IMPUTATION OF STRONGLY
ASSOCIATED SNPS
The results summarized so far compare a variety of
imputed genotypes with experimentally derived counter-
parts. However, a more interesting comparison focuses on
imputed genotypes that appear to show strong evidence
for association, as those might motivate further down-
stream experiments. To evaluate the accuracy of imputed
genotypes for these ‘‘strongly associated SNPs,’’ we
compared imputed and experimental genotypes in regions
that were only selected for follow-up genotyping after
imputation (for example, because imputed genotypes
resulted in strong evidence for association but nearby
genotyped markers did not). Table II summarizes the
comparison of allele frequencies, association test statistics,
and individual genotype calls between imputed genotypes
and actual genotypes later determined by genotyping.
Overall, it is clear that even among these strongly
associated SNPs imputation provided accurate estimates
of the true P-values. The largest observed discrepancies
were for rs17384005, rs11646114, and rs4812831, which
TABLE II. Comparison of imputed and experimental genotypes for a subset of SNPs showing strong association in
FUSION [Scott et al., 2007]
FUSION allele
frequency
Analysis of
imputed data
Analysis of actual
genotypes
Max. r2
w/GWAS SNPs
Imputed vs.
Actual genotypes, r2 Observed
allelic
SNP Imputed Genotyped P-value OR P-value OR Actual Estimated concordance
rs12910827 0.035 0.033 2.5 106 2.57 6.3 106 2.20 0.39 0.843 0.720 0.994
rs1449725 0.579 0.573 5.3 106 1.33 1.1105 1.31 0.90 0.965 0.977 0.990
rs17081352 0.075 0.078 7.3 106 1.70 5.5 106 1.68 0.87 0.989 0.954 1.000
rs11616188 0.502 0.545 1.5 105 1.40 4.8 105 1.27 0.27 0.755 0.585 0.919
rs10837766 0.138 0.152 1.5 105 1.49 8.6 105 1.40 0.46 0.822 0.930 0.975
rs11036627 0.080 0.071 1.7 105 1.67 1.9 105 1.66 0.75 0.876 0.901 0.987
rs17384005 0.175 0.149 1.9 105 1.84 .011 1.15 0.11 0.241 0.309 0.874
rs7750445 0.138 0.158 2.0 105 1.47 4.1105 1.41 0.50 0.836 0.965 0.977
rs2267339 0.640 0.643 2.8 105 1.33 4.5 106 1.34 0.72 0.951 0.873 0.990
rs17356414 0.580 0.715 3.0 105 1.30 8.0 104 1.25 0.34 0.562 0.920 0.878
rs1800774 0.664 0.696 3.9 105 1.39 7.3 106 1.35 0.29 0.861 0.617 0.972
rs175200 0.476 0.479 6.6 105 1.28 5.5 105 1.28 0.85 0.989 0.976 0.997
rs6103716 0.371 0.371 7.3 105 1.28 4.8 105 1.29 0.33 0.996 0.978 0.999
rs13297268 0.059 0.062 7.5 105 1.72 9.0 105 1.65 0.28 0.973 0.916 0.998
rs11646114 0.119 0.092 9.1105 1.66 .0020 1.38 0.13 0.687 0.512 0.956
rs2021966 0.609 0.603 9.1105 1.32 2.6 104 1.25 0.46 0.811 0.769 0.937
rs1270874 0.231 0.224 1.4 104 1.33 3.9 104 1.30 0.24 0.933 0.954 0.988
rs4812831 0.165 0.129 1.6 104 1.53 .0055 1.28 0.45 0.587 0.516 0.944
rs4402960 0.683 0.681 1.7 104 1.27 1.2 104 1.28 1.00 0.994 1.026 0.998
rs9402346 0.669 0.646 4.5 104 1.26 .0014 1.22 0.62 0.881 0.915 0.965
rs10019985 0.629 0.619 4.8 104 1.25 4.2 104 1.25 0.66 0.990 0.953 0.998
rs2466291 0.579 0.618 6.3 104 1.26 .0016 1.22 0.47 0.829 0.830 0.935
rs1409184 0.671 0.646 8.2 104 1.26 .0011 1.22 0.58 0.865 0.873 0.963
rs8079544 0.091 0.106 8.9 104 1.50 .013 1.27 0.22 0.707 0.731 0.961
rs1801282 0.165 0.165 9.5 104 1.31 .0011 1.30 1.00 0.999 1.002 1.000
rs3802177 0.372 0.371 9.9 104 1.23 .0012 1.22 1.00 0.996 1.015 0.999
The table shows a comparison of the results from analysis of imputed data with results for actual genotyping for a subset of the SNPs that
reached a P-value of o103 in our analysis of the FUSION data. Successive columns include SNP name, estimated allele frequency in
FUSION cases and controls, using either imputed data or actual genotype data, P-value and odds ratio for association test comparing allele
frequencies in cases and controls using imputed genotypes, P-value and odds ratio for association test comparing allele frequencies in cases
and controls using experimentally derived genotypes, r2 between the best single marker tag in the GWAS panel and this SNP, r2 between
imputed and observed genotypes (actual r2 and estimated from our method as a measure of imputation quality) and, finally, proportion of
alleles matching between imputed and actual genotypes. Note that because these are all imputed SNPs that show strong association in the
FUSION data, they are subject to a ‘‘winner’s curse’’ effect. Thus, SNPs where imputation resulted in inflated P-values were more likely to
be selected for follow-up in this analysis. Not all imputed SNPs showing association at this significance level were genotyped
experimentally. Rather, a subset of SNPs was selected for genotyping either because (a) they showed substantially stronger evidence for
association than other nearby genotyped SNPs and stronger evidence for association than nearby imputed SNPs or (b) they were selected to
improve coverage of the genome in and around 222 candidate genes [Gaulton et al., 2008]. All SNPs with a P-valueo103 in the imputed
data and which were subsequently genotyped are tabulated.
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were also the three markers for which our imputation
approach estimated lower r2 with actual genotypes.
Imputation is particularly useful because it allows
evidence for association at SNPs with no reliable proxies
to be evaluated more accurately. For instance, after
imputation, average r2 increased from 0.22 to 0.66 in the
set of SNPs whose best genotyped proxy had r2o0.30 and
from 0.33 to 0.75 in the set of SNPs whose best genotyped
proxy had r2o0.5 [for specific examples of disease
susceptibility loci that would be missed without imputa-
tion, see Li et al., 2009b].
USING IMPUTATION TO ESTIMATE
PAIRWISE DISEQUILIBRIUM
Remarkably, we observed that imputed genotypes could
also be used to obtain very accurate estimates of LD
between pairs of untyped markers, or of LD between a
genotyped marker and an untyped marker. As shown in
Figure 2, estimates of LD between two SNPs obtained
using imputed data are much closer to the results obtained
by actually genotyping the two SNPs than estimates
obtained by looking up the two markers in the HapMap
CEU database (Supplementary Figure 2 shows a similar
comparison for D’ estimates). Even with some imprecision
in estimates of individual genotypes, the increased sample
size compensates to reduce variation in the estimated LD
measures.
COMPARISON OF DIFFERENT
GENOTYPING PLATFORMS
Our experience with the FUSION GWAS, summarized
above, shows that imputation can be an effective way to
estimate unobserved genotypes and/or allele counts.
These genotypes can then be used in a variety of
downstream analyses, including logistic regression analyses
for discrete traits and linear regression analyses for
quantitative traits, and to facilitate meta-analysis of studies
based on different platforms. A key issue when consider-
ing imputation-based approaches is whether similarly
accurate estimates of unobserved data points can be
obtained with different genotyping panels or in different
populations [Clark and Li, 2007], and to evaluate this we
conducted two additional experiments.
In the first experiment, we used genotype data
generated by the International HapMap Consortium. We
considered each of the HapMap samples in turn and
masked available genotypes so as to mimic an experiment
using one of several commercially available chips. For
example, to evaluate the Affymetrix 500K SNP chip, we
marked genotypes for all markers that are not on the chip
as missing for the individual being considered. We then
A
B
Fig. 2. Imputation improves quality of LD estimates. For imputed SNPs on chromosome 14, the figure compares estimates of LD
obtained by genotyping both SNPs (‘‘Results from Actual Genotyping,’’ X axis) with estimates of LD obtained by imputing genotypes
for both SNPs using markers on the 317K marker chip (‘‘Results from Imputed Data,’’ Y axis, Top left), obtained by imputing genotypes
for one of the SNPs (‘‘Results from Imputed Data,’’ Y axis, Bottom Left) or obtained from the HapMap CEU panel (‘‘Results from
HapMap CEU,’’ Y axis, Top and Bottom Right).
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used haplotypes for the remaining individuals on the same
HapMap analysis panel (either YRI, CEU, or JPT1CHB) to
impute the missing genotypes. The results are summarized
in Table III and clearly show that a large number of
SNPs can be imputed very accurately using any of the
commercially available panels (e.g. with r240.80 to
experimental genotypes) and that, compared to relying
on single marker tagging, imputation results in improved
coverage of the genome.
Depending on the commercial panel and population
being investigated, coverage of HapMap SNPs (proportion
of SNPs with r240.80) increased by 10–30% for low MAF
alleles (MAFo5%) and by 10–20% for more common
alleles (MAF45%). In agreement with this result, the
average r2 between each untyped SNP and imputed
genotypes was up to 40% higher on average when using
imputed genotypes than when using the best available
single marker proxy. Imputation remained valuable even
for panels with 1 million directly genotyped SNPs. In
practice, the results shown in Table III are likely to
represent an upper bound on the performance of our
method in real settings, because additional errors will
result from discrepancies in genotyping protocols between
individual laboratories and the HapMap and from
differences in LD patterns between the HapMap and the
samples being studied. Nevertheless, they suggest our
method is likely to be helpful for a variety of currently
available commercial SNP panels.
TABLE III. Coverage of the Phase II HapMap with commercial genotyping panels, before and after imputation
Coverage by single-marker tags Coverage by imputed SNPs
] Panel SNPs ] Imputed SNPs MAFo5% MAFZ5% MAFo5% MAFZ5%
Used Lost MAFo5% MAFZ5% r2 r240.8 r2 r240.8 r2 r240.8 Error (%) r2 r240.8 Error (%)
CEU
A100 100,844 1,609 259,261 2,086,690 0.36 0.22 0.50 0.31 0.47 0.32 1.80 0.63 0.46 7.85
A250S 195,864 4,393 251,807 2,002,214 0.48 0.31 0.65 0.44 0.61 0.46 1.33 0.79 0.65 4.12
A250N 216,747 4,836 250,364 1,983,146 0.50 0.34 0.67 0.48 0.63 0.49 1.26 0.80 0.68 3.94
A500 412,611 9,229 234,049 1,809,352 0.61 0.44 0.77 0.61 0.73 0.60 0.93 0.89 0.82 2.12
A1000 676,182 87,766 209,636 1,580,321 0.71 0.57 0.86 0.76 0.79 0.68 0.73 0.93 0.91 1.23
I300 305,050 3,115 267,573 1,871,586 0.30 0.08 0.84 0.74 0.70 0.54 1.08 0.93 0.90 1.39
I550 513,779 238 254,183 1,681,501 0.59 0.40 0.90 0.85 0.79 0.67 0.76 0.95 0.94 0.90
I650 578,864 14,627 244,431 1,630,298 0.66 0.48 0.91 0.86 0.80 0.68 0.72 0.95 0.94 0.88
I1000 779,800 130,014 225,439 1,456,134 0.70 0.54 0.93 0.89 0.81 0.71 0.67 0.96 0.95 0.73
YRI
A100 100,627 3,223 326,772 2,320,439 0.21 0.08 0.33 0.14 0.35 0.18 2.22 0.50 0.26 10.32
A250S 210,242 4,698 318,680 2,220,904 0.30 0.13 0.47 0.22 0.50 0.29 1.73 0.69 0.44 6.05
A250N 231,026 4,971 317,321 2,201,821 0.32 0.15 0.49 0.26 0.53 0.33 1.64 0.71 0.49 5.68
A500 441,268 9,669 300,455 2,013,203 0.41 0.21 0.60 0.36 0.65 0.46 1.24 0.83 0.69 3.30
A1000 737,369 91,811 275,794 1,749,271 0.54 0.31 0.73 0.54 0.74 0.58 0.92 0.90 0.83 1.91
I300 271,991 15,346 315,631 2,163,803 0.33 0.15 0.52 0.26 0.60 0.39 1.42 0.79 0.60 3.97
I550 474,049 19,355 301,391 1,981,088 0.42 0.20 0.68 0.46 0.70 0.51 1.09 0.88 0.80 2.13
I650 573,953 28,487 300,785 1,881,962 0.46 0.23 0.75 0.56 0.73 0.55 0.98 0.90 0.85 1.72
I1000 788,503 149,152 274,766 1,702,039 0.53 0.30 0.78 0.60 0.76 0.59 0.88 0.92 0.88 1.47
JPT1CHB
A100 95,521 1,994 299,643 1,919,001 0.35 0.22 0.47 0.28 0.44 0.32 1.68 0.60 0.42 8.86
A250S 186,411 4,368 290,265 1,840,510 0.49 0.33 0.63 0.42 0.58 0.45 1.23 0.76 0.61 5.00
A250N 205,274 4,713 288,661 1,823,236 0.51 0.36 0.65 0.46 0.59 0.48 1.17 0.77 0.64 4.70
A500 391,685 9,081 268,427 1,663,552 0.62 0.47 0.76 0.60 0.69 0.59 0.84 0.87 0.80 2.60
A1000 638,817 86,838 239,528 1,455,644 0.72 0.59 0.85 0.75 0.75 0.67 0.65 0.92 0.89 1.50
I300 274,751 12,851 287,456 1,755,289 0.54 0.38 0.75 0.58 0.69 0.57 0.88 0.88 0.82 2.25
I550 467,073 13,322 269,299 1,587,153 0.67 0.52 0.87 0.78 0.75 0.67 0.64 0.93 0.91 1.26
I650 531,807 23,155 259,962 1,534,915 0.71 0.57 0.88 0.80 0.76 0.69 0.61 0.94 0.92 1.19
I1000 728,837 136,560 239,252 1,365,519 0.73 0.61 0.90 0.85 0.78 0.70 0.57 0.95 0.94 0.91
For each platform, the table lists the number of SNPs in the platform that overlap with the phased HapMap chromosomes (release 21a). The
number of SNPs that were not in the phased HapMap are also listed, most of these were monomorphic. This number is followed by the
number of SNPs that we attempted to impute, either with minor allele frequency o5% or 45%. We did not attempt to impute singletons.
Coverage statistics using conventional single-marker tagging are provided and refer to the maximum r2 between a HapMap SNP not on the
panel and its best tag on the panel. Coverage statistics using imputation are also tabulated and refer to the relationship between imputed
genotypes for each SNP and true genotypes for the same SNP. To evaluate the coverage of each genotyping platform using imputation, we
focused on the markers that overlapped between the platform and the Phase II HapMap. We then considered each HapMap founder in turn
and masked all genotypes for all markers not present in the commercial platform being evaluated. Finally, we used the remaining (unmasked)
genotypes together with haplotypes for the other HapMap founders to impute the masked genotypes. The proportion of alleles that were
imputed incorrectly, together with the correlation between imputed genotypes and actual genotypes are tabulated for each platform.
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IMPUTATION IN DIVERSE
POPULATIONS
In a second experiment, we evaluated the performance of
our method in 927 samples from 52 populations in the
Human Genome Diversity Project (HGDP). In a previous
evaluation of tag SNP portability, these 927 samples were
genotyped for 1,864 SNPs in 32 autosomal regions (average
minor allele frequency 0.15–0.24, depending on population)
[Conrad et al., 2006]. The regions were selected to represent
regions of high and low LD across the genome. Each region
spanned330kb, including a central ‘‘core’’ region of90kb,
where 60 SNPs were attempted, and two 120kb flanking
regions on either side, where 12 SNPs were attempted. To
evaluate the performance of genotype imputation across
these diverse populations, we selected a thinned marker set
including 872 SNPs spaced10kb apart across all 32 regions.
We then used these SNPs to impute genotypes for the
remaining 992 SNPs and evaluated our approach.
Figure 3 shows the proportion of incorrectly imputed
alleles in each of the populations. Results are presented
using a single HapMap analysis panel as a reference
(either the CEU, YRI, or CHB1JPT) or using all HapMap
samples as a larger reference panel. For each of the
populations, the reference panel that resulted in the
smallest overall error rate is highlighted. Overall, African
samples were the most difficult to impute, with error rates
ranging between 5.13% for the Yoruba and 11.86% for the
San when the HapMap YRI panel was used as a reference.
In other parts of the world, we generally observed that the
HapMap CEU provided a good reference panel for
European populations and that the HapMap CHB1JPT
provided a good reference panel for East Asian popula-
tions, resulting in error rates of o3.34 and o2.89%,
respectively. Outside Europe and East Asia, when imputa-
tion was applied to populations from the Middle East,
Central and South Asia, the Americas or Oceania, it was
generally better to use the combined HapMap sample as a
reference than to use any single HapMap analysis panel as
a reference. It is interesting to note that, in all cases,
combining the three HapMap panels into a single
reference set was either the best option or the second best
option. Furthermore, in situations where this combined
reference panel reduced imputation accuracy, it resulted in
an average increase of only 0.15% in error rates. Our
results are consistent with those of Huang et al. [Huang
et al., 2009] who showed, in a smaller subset of HGDP
populations and a different set of genotyped SNPs, that
combined reference panels could outperform panels that
included only one population. The figure also illustrates
that, when a large number of individuals are genotyped in
study samples, it may be possible to bypass the HapMap
reference panel altogether. In the last panel, rather than
using the HapMap genotypes to impute missing data, we used
a combined dataset including all other HGDP populations.
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Fig. 3. Evaluation of imputation accuracy across HGDP panels. For each of 52 populations in the Human Genome Diversity Panel (HGDP) a
set of 872 SNPs distributed evenly across 32 regions, each 330kb in length, was used to impute 992 other SNPs. The 992 imputed SNPs
were located near the middle of each imputed region. Imputation was done using either the HapMap YRI, CEU, CHB1JPT, or a combination
of three HapMap panels (first four panels, best panel is shaded in gray) or using the remaining HGDP samples as a reference. In each case,
the proportion of correctly imputed alleles is tabulated. The figure is based on a re-analysis of data of Conrad et al. [2006].
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Figure 4 focuses on the estimated r2 between imputed
and observed allele counts. In each stripe, accuracy of
imputation is assessed using a different reference panel.
Superimposed in pink is the coverage that would be
provided by single marker tagging approaches. Broadly, it
is clear that imputation using an appropriate reference
panel will improve coverage. Using an inappropriate
reference panel (for example using the HapMap CEU to
impute genotypes for one of the African populations), can
result in imputed genotypes and allele counts that are not
as strongly correlated with the true genotypes as the best
available single marker tag but, even then, the loss appears
to be small. Importantly—in all cases—combining the
three HapMap panels resulted in substantial improve-
ments in coverage over single marker tagging—suggesting
that this might be a cautious approach when the choice of
reference panel is unclear. Combining the three HapMap
panels is also a good choice for genotype imputation in
admixed populations [Mathias et al., 2010] where, depend-
ing on the ancestry of each stretch of the genome, the
best matching haplotype will likely originate from a
different HapMap reference panel. Our conclusion that
the combined panel is a sensible reference for all
populations facilitates practical decision making on
the choice of reference panel. The conclusion is also
supported by Huang et al. [Huang et al., 2009]. Although
their aim was to find an optimal population-specific
reference panel for each HGDP sample, their Figure 6
shows that a combined panel, including all HapMap
haplotypes is the best compromise choice, in the sense that
it performs almost optimally in each of the 39 HGDP
populations examined. In the future, we expect that
imputation methods that weigh the different reference
panels could further improve imputation quality.
IMPACT OF IMPUTATION ON
POWER OF ASSOCIATION STUDIES
Our evaluation of imputed genotypes in the FUSION,
HapMap, and HGDP samples clearly shows that imputa-
tion can be very accurate in a variety of populations. In
this way, we believe it will be an important tool for
combining results across studies that rely on different
marker panels. To investigate whether using imputed
genotypes might also improve power in individual
studies, we carried out a simulation experiment. As
previously described [Schaffner et al., 2005], we simulated
10,000 chromosomes for a series of 1Mb regions. Within
each region, simulated LD patterns mimicked the HapMap
CEU or YRI [Schaffner et al., 2005]. We then used a subset
of 120 simulated chromosomes to generate a region
specific ‘‘HapMap.’’ As described in the methods, we
then picked the minor allele for a randomly selected
polymorphic site in each region as the ‘‘disease suscept-
ibility allele’’ and simulated a set of 500 case and 500
control individuals using the remaining chromosomes.
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Fig. 4. Evaluation of imputation accuracy across HGDP panels. Genotypes for a set of 992 SNPs were imputed in the HGDP and then
compared with actual genotypes. For each pair of true and imputed genotypes an r2 coefficient was calculated and averaged for each
population. The best set of HapMap reference individuals for each population is shaded. The coverage obtained by using the best
available tag SNP (rather than imputed genotypes) is overlaid in pink. See Figure 3 legend for further details.
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The susceptibility allele varied in frequency between 2.5
and 50%, with larger simulated effect sizes assigned to
rarer alleles to ensure comparable power in a hypothetical
fully genotyped sample. We also simulated 2,000 datasets
where the disease allele had no effect to calibrate region-
wide type I error rates for each approach.
To analyze each region, we thinned SNPs in the
simulated HapMap to match the density and allele
frequency spectrum of the Phase II HapMap [The
International HapMap Consortium, 2007]. Using the
thinned data, we selected a panel of 100 tag SNPs for
each region that included the 90 tag SNPs with the largest
number of proxies and 10 additional SNPs selected at
random among the remaining tags. This approach resulted
in panels that captured 78% of the common variants
(MAF45%) in the simulated CEU HapMap, similar to the
real life performance of the Illumina 317K SNP genotyp-
ing chip. Finally, we analyzed each of the simulated
datasets using the selected marker panel and one of three
analysis strategies: (a) single marker chi-squared associa-
tion tests, (b) single and multi-marker association tests
[Pe’er et al., 2006] as suggested by the PLINK [Purcell
et al., 2007] program based on the simulated HapMap, or
(c) tests using imputed allele counts for all the markers in
the simulated HapMap. Results are summarized in
Table IV. The first row in the table shows the significance
thresholds used for each analysis (since approaches (b)
and (c) both increase the total number of tests, note that the
P-value threshold increases slightly when multi-marker
tests are used and increases further when imputation is
used). Subsequent rows summarize power for markers of
different allele frequencies. In populations with strong LD,
it is clear that for common susceptibility alleles the single
marker tests provide high power and that imputation or
multi-marker analyses provide only small gains in power.
However, for rarer alleles (such as those with frequencies
o5%), imputation can provide dramatic increases in
power. For instance, power increased from 24.4 to 56.2%
when the disease allele frequency was 2.5% and imputa-
tion was used in the panel with CEU-like LD. As large
genome scans and meta-analyses that are well-powered to
evaluate rarer variants with modest effects are completed,
we believe that imputation will become an increasingly
important primary analysis and there are now examples of
confirmed disease susceptibility loci that would have been
missed without genotype imputation [Li et al., 2009b].
PRACTICAL CONSIDERATIONS
A key ingredient for any imputation-based approach is
to ensure that alleles are consistently labeled across
studies. In our evaluation of FUSION and HGDP samples,
using the HapMap as a reference, we were fortunate that a
subset of the HapMap individuals were genotyped in each
study for quality control. Contrasting the genotypes for
these quality control samples with those generated by the
HapMap Consortium made the usually laborious process
of ensuring consistent allele labeling across labs much
easier. We strongly recommend that all labs conducting
GWAS genotype a small number of HapMap individuals
for this purpose.
Another practical consideration arises when integrating
data from studies that use diverse genotyping platforms.
Superficially, it is tempting to first impute missing genotypes
in each sample and to then conduct a pooled analysis of all
available data. However, this is almost never a good idea, as
illustrated by a particularly extreme case where a set of cases
and controls have been genotyped on two different plat-
forms and a marker of interest has been genotyped in cases
TABLE IV. Imputed genotypes result in increased power
Power (LD mimics CEU) Power (LD mimics YRI)
Single marker
tags
Multi
marker tags
Imputed
genotypes
Single
marker tags
Multi
marker tags
Imputed
genotypes
Empirical P-value threshold 0.00081 0.00071 0.00030 0.00067 0.00067 0.00017
MAF5 2.5% 24.4% 25.0% 56.2% 21.2% 22.6% 43.6%
MAF5 5% 55.8% 56.4% 74.0% 35.6% 36.0% 55.0%
MAF5 10% 77.4% 78.4% 87.8% 62.4% 63.8% 73.0%
MAF5 20% 85.6% 86.2% 91.4% 68.8% 70.6% 78.2%
MAF5 50% 93.0% 93.6% 96.4% 75.4% 77.4% 86.6%
The table summarizes results from the analysis of two sets of 100 simulated 1Mb regions. For each region, we generated a simulated
HapMap including 200 SNPs and used this panel to pick 100 tag SNPs that provided good coverage of the region (average r20.8 in CEU,
0.6 in YRI). We then simulated and analyzed a series of case control studies, each with 500 cases and 500 controls. Association tests were
carried out at each tag SNP marker (‘‘Single Marker Tags’’), initially. These results were then augmented with the analysis of multi-marker
tags as suggested by PLINK [Pe’er et al., 2006; Purcell et al., 2007] (‘‘Multi Marker Tags’’) or with the analysis of imputed genotypes
(‘‘Imputed Genotypes’’). In each case, we first simulated and analyzed 2,000 null (20 per region) datasets by assigning a pair of random
chromosomes to each case and control. These analysis were used to establish the empirical P-value threshold that, when applied to the most
significant result in each region, resulted in a type I error rate of 5%. Then, for each tabulated minor allele frequency (MAF), we simulated
500 case-control datasets (5 per region, 500 cases and 500 controls each) where a variant with the specified MAF was associated with
susceptibility. Power refers to the proportion of replicates where the top P-value exceeds the empirical P-value threshold. Note that the
susceptibility variant was picked at random among all simulated SNPs with the requisite MAF and was not necessarily included in the tag
SNP set or in the markers ascertained for each region specific HapMap. To ensure comparable power across varying MAF, we increased
genotype relative risk for rarer SNPs. Specifically, we set GRR5 2.500, 2.020, 1.715, 1.530, and 1.440 for SNPs with MAF5 2.5, 5, 10, 20 and
50%, respectively. These settings correspond to 80% power for single marker tests when the susceptibility variant is typed and a P-value
threshold of 0.0005 is used (0.05/100, corresponding to a Bonferroni threshold that assumes 100 independent SNPs are tested).
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but must be imputed in controls. If the marker of interest
cannot be well predicted by flanking markers, imputation
will default to suggesting that the genotype distribution at
that marker matches the reference panel—but this could be a
very poor assumption if the reference panel and study
sample have drifted apart, potentially resulting in spurious
association. Even if the marker can be well predicted by
flanking markers, it is possible that the reference panel and
the case sample used different genotyping assays that, for
technical reasons such as the presence of a polymorphism
that overlaps assay primers, give consistently distinct
results—again resulting in spurious association. To avoid
these sources of spurious association, we recommend that,
when analyzing genotype data generated using different
platforms, different versions of the same platform, or using
the same platform but with experiments carried out at
different labs, an initial round of association analysis should
be carried out using data from each platform/version/site
combination. The results from this initial round of analysis
can then be meta-analyzed, minimizing the risk of artifacts.
This recommendation does preclude analyses where all
cases are genotyped at one site, and all controls are
genotyped at a different site.
In the experiments described so far, we illustrated the
accuracy of genotype imputation that relies on existing
resources (such as the Phase II HapMap) and genotyping
technologies (including a variety of commercial genotyping
chips). It is likely that both these resources and technolo-
gies will continue to evolve rapidly and it is interesting to
consider how these developments might impact imputa-
tion-based approaches. For example, it is clear that
genotyping chips of the future will be able to examine an
ever larger number of tag SNPs in a cost-effective manner.
Extrapolating from Table III, it is clear these should provide
improved genomic coverage, eventually allowing investi-
gators to impute nearly all HapMap SNPs with near perfect
accuracy. Nevertheless, it is also clear from Table III that
when coupled with imputation-based analyses even
relatively low-density SNP chips can provide excellent
coverage of the genome in populations with LD patterns
similar to the CEU, JPT, and CHB. Thus, we expect the
main advantages of new higher-density chips will be in
the study of populations with less extensive LD, such as
the YRI, and in the analysis of rarer variants.
THE FUTURE: LARGER REFERENCE
PANELS
Another interesting possibility to consider is the impact
of larger HapMap reference panel on imputation or,
similarly, the utility of using extra genotype data on a
subset of individuals in a study to aid imputation in the
remaining individuals in the study. To evaluate these
possibilities, we generated a reference panel with varying
numbers of Finnish individuals (between 30 and 500, see
Table V) and used these reference panels to impute
genotypes for 521 SNPs in an independent set of 500
individuals from the FUSION study of type II diabetes.
Imputation accuracy and genomic coverage increase
noticeably with the larger reference panels, with overall
discrepancy rates between typed and untyped alleles as
low as 0.40% when a reference panel of 500 unrelated
individuals is available. One of the reasons for this
increase in accuracy is that the length of haplotypes
shared between individuals in the reference panel and
those in the study sample increases gradually as the size of
the reference panel increases. For example, mosaic frag-
ments used to reconstitute the FUSION samples using the
individuals in the 500-sample reference panel were slightly
41Mb long on average. These long stretches are easier for
our Markov model to identify and are also likely to
descend from a more recent common ancestor. This means
they will have undergone fewer rounds of gene conversion
and mutation, which gradually erode haplotype simila-
rities and reduce the quality of our imputed genotypes.
Overall, our results suggest that either genotyping a
number of the study samples for markers of interest or
increasing the size of the public reference panels will
greatly improve the quality of genotype imputation.
THE FUTURE: COMBINING
IMPUTATION WITH NEW
SEQUENCING TECHNOLOGIES
With the rapid development of very high-throughput re-
sequencing technologies [Bentley, 2006], it is oft proposed
that genotyping-based approaches will soon become
outdated. Re-sequencing-based approaches capture var-
iants that are absent from public databases including,
potentially, population specific variants. Our haplotyping
approach can use whole genome re-sequencing data as
input. In this setting, it uses information from individuals
with similar haplotypes to reconstruct patterns of variation
in regions where deep coverage is not available. In
principle, the approach could be useful to help describe
regions that, due to chance, are poorly covered in a
particular sequencing experiment or to allow for econom-
ical evaluation of many individuals. To evaluate the
possibilities, we simulated data for ten 1Mb regions and
simulated shotgun sequence data for each region. We
simulated reads that were only 32 base pairs long and with
a per base-pair error rate of 0.2%. Very roughly, these
correspond to the performance of early versions of next
generation re-sequencing technologies; newer versions of
these technologies can generate longer and more accurate
reads and should thus outperform the simulations
presented here. We then re-sequenced between 100 and
400 individuals at different depths and used our approach
to reconstruct haplotypes and genotypes for each indivi-
dual. Note that the simulated reads are typically too short
to include useful information on phase (because they will
generally include only zero or one sites that truly differ
from the reference sequence). In addition, given the large
number of bases examined, they will also suggest a large
number of false polymorphic sites. To control false-
positive variant calls, it is imperative to confirm true
polymorphic sites either by examining overlapping similar
reads from the same individual or, potentially, from other
individuals who share a similar haplotype.
For each site, we counted the number of times that the
reference base or an alternative base was sequenced for
each individual. For computational convenience, we only
considered sites where both bases were observed several
times (see Appendix for detailed methods and implemen-
tation details) in downstream analyses and assigned the
most frequently sampled base to all other sites. On this
scale, the shotgun re-sequencing approach typically
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characterized 4,000 polymorphic sites across the sampled
individuals - 4 the SNP density of the Phase II
HapMap. Even relatively light shotgun re-sequencing
provided very accurate haplotypes for each individual.
For example, when 400 individuals were sequenced at 4
depth, there were only 18.97 errors per individual on
average (over 1,000,000 base-pairs). Across 980,000 sites
that were monomorphic in the population only 82 false
polymorphisms were called on average. Accuracy was
also excellent at sites that were polymorphic in the
population. For example, 3,558 of the 3,641 simulated
polymorphic sites with MAF 40.5% were identified and,
at these sites, alleles were called with an accuracy of
99.93% (see Tables VI and VII). For any given depth,
imputed accuracy increased with the number of sequenced
individuals (for example, accuracy at sites with MAF
40.5% was 98.8% when 100 individuals were sequenced
at 2 coverage but increased to 99.7% when 400
individuals were sequenced at the same depth; the
number of errors per individual decreased similarly from
106.3 per individual to 40.3 per individual). In addition,
the depth required to achieve a given accuracy decreased
as the number of sequenced individuals increased: achieving
99.9% accuracy for sites with population MAF 40.5%
requires 8 depth for 100 individuals, 6 depth in
200 individuals and only 4 depth in 400 individuals. In
each case, note that error rates are higher at heterozygous
sites than at homozygous sites. Again, performance of the
approach with larger numbers of individuals improves
because the mosaic fragments described by our model
increase in length and, thus, become easier to find. This is
also reflected in the accuracy of estimated haplotypes,
which—when compared with simulated haplotypes—
have 1 switch per 50 kb when 100 individuals are
examined, but 1 switch per 500 kb when 400 individuals
are examined. We expect that combining shotgun re-
sequencing of whole genomes with imputation-based
approaches such as ours will allow economical association
studies that evaluate SNP variation in large numbers of
individuals even more exhaustively than is currently
possible. Furthermore, we expect that whatever the
characteristics of the re-sequencing technology used, it
will be possible to improve the quality of estimated
genotypes and haplotypes at each site by combining
information across individuals, rather than simply in-
creasing the depth at which each individual is sequenced.
TABLE V. Effect of increasing reference panel size on imputation accuracy
Genotypic matching error rates
] Reference
panel size
Major allele
homozygote
(%)
Heterozygote
(%)
Minor allele
homozygote (%) Overall (%)
Allelic matching
error (%)
Mean
r2 (%)
Median
r2 (%)
All SNPs
30 2.18 16.43 16.27 5.56 2.95 84.7 94.6
60 1.23 7.99 8.44 2.54 1.31 91.5 97.5
100 0.95 4.31 5.48 1.73 0.88 93.6 98.2
200 0.56 3.17 3.25 1.03 0.52 96.1 98.8
500 0.46 1.96 2.41 0.79 0.40 97.1 99.1
Best single SNP tag r2o0.5
30 3.54 46.55 43.96 11.00 5.94 63.5 66.2
60 2.09 28.29 25.64 5.73 2.99 76.4 82.5
100 1.93 14.17 19.32 3.89 2.00 82.0 87.9
200 1.35 11.96 13.19 2.68 1.37 87.5 91.3
500 1.04 6.76 9.06 2.00 1.02 91.0 94.6
MAFZ20%
30 3.18 10.14 11.92 6.96 3.74 85.4 94.7
60 1.83 4.03 5.50 3.13 1.62 92.7 97.7
100 1.32 2.75 3.63 2.15 1.10 95.2 98.7
200 0.82 1.68 2.36 1.30 0.66 97.0 98.9
500 0.69 1.31 1.60 1.01 0.51 97.7 99.2
MAFo20%
30 1.07 23.47 21.80 3.99 2.06 83.9 94.3
60 0.56 12.43 12.16 1.88 0.96 90.0 96.7
100 0.54 6.05 7.84 1.26 0.64 91.5 97.4
200 0.26 4.83 4.38 0.72 0.36 94.9 98.7
500 0.20 2.68 3.44 0.54 0.27 96.4 98.9
To evaluate the impact of a larger reference panel on the accuracy of genotype imputation, we used different numbers of individuals from
the FUSION study genotype for markers on the Illumina 317K SNP chip and also 521 SNPs on a candidate region of chromosome 14 [Willer
et al., 2006] to impute genotypes for an independent set of 500 FUSION individuals on whom only the Illumina 317K SNP chip genotypes
were available. The imputation procedure converged after300 rounds with panel size5 30 and 60,200 rounds with panel size5 100, and
o100 rounds for panel sizes5 200 or 500 individuals. Imputed genotypes were compared with experimental genotypes to determine
accuracy at the genotype and allele level and to evaluate the r2 between true and imputed genotypes. Imputation accuracy measures are
broken down by relatively common and rare SNPs using a MAF (minor allele frequency cutoff of 20%) and imputation error rates at the
genotypic level are evaluated both overall and by genotype categories.
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DISCUSSION
In summary, we have described and evaluated a very
effective model for haplotyping and genotype imputation
in whole genome studies. The idea of genotype imputation
is not new and was outlined as early as 2006 [Scheet and
Stephens, 2006]. Here, we evaluate the practical perfor-
mance of imputation based on a variety of genotyping
platforms and populations, using both simulations and
real data. We show that our model leads to imputed
genotypes whose quality improves as more data becomes
available, either because a larger reference panel is used or
because study samples are genotyped in finer detail.
Similarly, haplotype estimates improve in quality as more
individuals are genotyped. Furthermore, we have intro-
duced novel approaches for the analysis of short read
shotgun sequencing data, which is likely to become
extremely important as human geneticists move beyond
chip-based genotyping to resequencing (as in the 1,000
Genomes Project, whose initial design was partly based on
the simulations summarized in our Table VI, see http://
www.1000genomes.org for more details).
Other approaches for genotype imputation have been
developed independently [Marchini et al., 2007; Servin
and Stephens, 2007]. We expect that our results demon-
strating the utility of larger reference panels, showing that
the three HapMap analysis panels can be combined to
better impute genotypes in populations that are genetically
distant from the HapMap analysis panels, illustrating the
ability of imputation-based approaches to estimate LD
between untyped markers, and comparing the relative
performance of imputation-based approaches for different
commercial marker panels will apply when these alter-
native approaches for genotype imputation are used. The
approaches differ in the precise details of how they search
for shared haplotype stretches and also in the efficiency of
their computational implementations. For example,
whereas [Marchini et al., 2007] rely on recombination
rates generated by the HapMap Consortium and assume a
uniform mutation/error rate for all markers, we estimate
‘‘recombination rates’’ within each dataset and allow
‘‘mutation rates’’ to vary. These parameters capture not
only intrinsic characteristics of the markers and regions
being examined, but also—for example—the genetic
distance between the samples being imputed and the
reference panel (which can impact apparent ‘‘recombina-
tion rates’’) and differences in genotyping protocols
between the two samples (which can impact apparent
‘‘mutation rates’’).
We expect that, in small samples, the use of external
recombination rate estimates (as in IMPUTE) might be
beneficial, but that with large sample sizes or in the
presence of genotyping error our approach, which uses
available data to model ‘‘recombination’’ and ‘‘mutation’’
rates should become advantageous. We performed two
sets of preliminary comparisons of MaCH and IMPUTE. In
the first experiment, we applied IMPUTE [Marchini et al.,
2007] to the FUSION GWAS data for chromosome 14 and
estimated genotypes for 521 previously genotyped mar-
kers [Willer et al., 2006]. Genotypes estimated by IMPUTE
and MaCH were identical in 99.2% of cases. In the cases
where the two estimates differed, IMPUTE matched
experimental genotypes 44.6% of the time, MaCHmatched
experimental genotypes 52.3% of the time, and both
estimates were wrong 3.06% of the time. For the second
experiment, we applied IMPUTE to the HGDP data of
Conrad et al. [2006]. Table VIII tabulates the proportion of
markers imputed with r240.80 in each population using
TABLE VIII. MaCH vs. IMPUTE in the HGDP populations
Population Continental group
Best
MaCH (%)
Best
IMPUTE (%)
Bantu Africa 42.64 42.64
BiakaPygmy Africa 33.06 33.17
Mandenka Africa 51.31 50.71
MbutiPygmy Africa 29.74 30.44
San Africa 25.81 25.91
Yoruba Africa 52.42 53.93
Colombian Americas 58.06 57.46
Karitiana Americas 49.19 49.09
Maya Americas 67.14 66.43
Pima Americas 54.54 53.73
Surui Americas 45.56 45.36
Balochi Central South Asia 65.42 64.31
Brahui Central South Asia 66.63 65.02
Burusho Central South Asia 69.56 69.46
Hazara Central South Asia 69.05 68.15
Kalash Central South Asia 67.14 64.92
Makrani Central South Asia 69.56 67.44
Pathan Central South Asia 67.04 67.14
Sindhi Central South Asia 67.54 66.23
Uygur Central South Asia 70.77 69.35
Cambodian East Asia 65.83 64.52
Dai East Asia 62.90 62.60
Daur East Asia 64.42 64.92
Han East Asia 69.25 69.46
Han-NChina East Asia 63.21 62.00
Hezhen East Asia 65.42 65.02
Japanese East Asia 67.54 66.73
Lahu East Asia 60.69 61.09
Miao East Asia 62.80 61.69
Mongola East Asia 64.92 65.83
Naxi East Asia 62.30 62.10
Oroqen East Asia 69.76 69.35
She East Asia 62.80 63.10
Tu East Asia 67.24 66.94
Tujia East Asia 63.41 63.21
Xibo East Asia 65.12 64.72
Yakut East Asia 70.67 69.86
Yi East Asia 63.71 62.20
Adygei Europe 69.25 67.04
Basque Europe 73.39 72.68
French Europe 71.47 71.27
Italian Europe 70.67 70.26
Orcadian Europe 64.01 64.52
Russian Europe 72.58 71.88
Sardinian Europe 67.94 67.94
Tuscan Europe 64.01 64.92
Bedouin Middle East 63.71 62.40
Druze Middle East 66.73 66.83
Mozabite Middle East 63.71 63.51
Palestinian Middle East 67.94 66.03
Melanesian Oceania 56.75 56.15
Papuan Oceania 52.12 49.50
For each of the 52 HGDP populations, we picked the reference panel
(CEU, JPT1CHB, YRI, or three combined) that resulted in the
highest coverage (measured by r2 between experimental genotypes
and imputed fractional counts) for MaCH and IMPUTE v0.5.0.
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either MaCH or IMPUTE (in each case, we selected the
HapMap reference panel that provided the best imputed
genotypes). Overall, the two methods perform similarly.
MaCH slightly outperforms IMPUTE in 37 out of 52
populations, slightly underperforms in 13 populations and
the two methods are tied in the remaining two popula-
tions. Our results are consistent with other published
comparisons [Biernacka et al., 2009; Pei et al., 2008], which
include detailed comparisons of the performance of MaCH
and IMPUTE with each other and with alternative
imputation approaches such as BEAGLE and fastPHASE.
Our method uses an HMM to describe genetic variation
along each haplotype. It is clear that when HMM models
are applied to genetic data, many opportunities for
identifying computational efficiencies exist [Abecasis
et al., 2002; Gudbjartsson et al., 2000; Idury and Elston,
1997; Kruglyak and Lander, 1998; Lander and Green,
1987]. In the methods section we describe several
optimizations that we have already implemented, includ-
ing a general strategy for reducing memory requirements
for the Baum algorithm [Baum, 1972; Wheeler and
Hughey, 2000]. We expect that further efficiencies will be
forthcoming. Our model is implemented in the MaCH
package (freely available with C11 source code from our
website, see http://www.sph.umich.edu/csg/abecasis/
mach/). Our implementation can be used to carry out all
the analyses described in this paper. Specifically, it can
estimate haplotypes, impute missing genotypes in a
variety of populations, using the HapMap sample or
another set of densely genotyped individuals as a
reference, analyze shotgun re-sequencing data from high-
throughput technologies now being developed, and carry
out simple tests of association.
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APPENDIX: DETAILED METHODS
DESCRIPTION
HIDDEN MARKOV MODEL
Our model resolves a set of unphased genotypes G into
an imperfect mosaic of several template haplotypes. We
assume that H template haplotypes are each genotyped at
L loci and let Tj(i) denote the allele observed at locus j in
reference haplotype i. Furthermore we define a series of
indicator variables S1, S2,y, SL that denote an hypothetical
(and unobserved) mosaic state underlying the unphased
genotypes. At a specific position j there are H2 possible
states. A specific state, such as Sj5 (xj, yj), indicates that
the first chromosome uses haplotype xj as a template,
whereas the second chromosome uses haplotype yj as a
template.
We are interested in making inferences about the
sequence of mosaic states S that best describe the observed
genotypes. Knowledge of S will implicitly order alleles at
heterozygous sites and suggest an allele for each untyped
location. We define the joint probability of the observed
genotypes and an underlying haplotype state as:
PðG;SÞ ¼ PðS1Þ
YL
j¼2
PðSjjSj1Þ
YL
j¼1
PðGjjSjÞ:
In the model above, P(S1) denotes the prior probability of
the initial mosaic state and is usually assumed to be equal
for all possible configurations, P(Sj|Sj– 1) denotes the
transition probability between two mosaic states and
reflects the likelihood of historical recombination events
in the interval between j and j1, P(Gj|Sj) denotes the
probability of observed genotypes at each position condi-
tional on the underlying mosaic state and reflects the
combined effects of gene conversion, mutation, and
genotyping error. Interestingly, note that, whereas, our
model and IMPUTE both use a large number of haplotypes
as templates, fastPHASE [Scheet and Stephens, 2006] uses
a smaller set of estimated haplotype ‘‘groupings’’ as
templates in an otherwise similar HMM, resulting in
improved computational efficiency at the cost of some
fuzziness in haplotype templates.
MONTE-CARLO HAPLOTYPING PROCEDURE
To estimate haplotypes in a sample of genotyped
individuals we first assign a random pair of haplotypes
to each individual, consistent with the observed geno-
types. This involves randomly ordering alleles at each
heterozygous site and sampling alleles at untyped sites
according to population frequencies. Then, we update the
haplotypes for each individual in turn by using the
current set of haplotype estimates for all individuals as
templates and sampling S proportional to the likelihood
L(S|G)pP(G,S). Note that since the Sj define a Markov
Chain this sampling can be done conveniently using
Baum’s forward and backward algorithm [Baum, 1972]. A
new set of haplotypes for an individual is then defined
according to sampled mosaic and edited to ensure it
matches the observed genotypes. We repeat the update
procedure several times, looping over all individuals
(more updates result in gradual refinement of the
estimated haplotypes, but very accurate haplotype esti-
mates can often be obtained in 20 rounds, see Table I).
After a pre-specified number of rounds are completed, we
generate a pair of consensus haplotypes for each indivi-
dual. This consensus haplotype pair is defined as the pair
that minimizes total switch error when compared to the
haplotypes sampled at each round.
PARAMETER ESTIMATION
Key ingredients in the above procedure are the transi-
tion probabilities P(Sj|Sj– 1) and emission probabilities
P(Gj|Sj). We define the transition probabilities as a
function of the crossover parameter yj:
PðSjjSj1Þ
¼
y2j =H
2 if xj 6¼xj1 andyj 6¼yj1;
ð1yjÞyj=H1y2j =H2 if xj 6¼xj1 or yj 6¼yj1;
ð1yjÞ212ð1yjÞyj=H1y2j =H2 if xj¼xj1 and yj¼yj1:
8><
>:
The possible values of P(Sj|Sj– 1) reflect both the overall
rate of changes in the mosaic for the interval, given by yj,
and the fact that when a change occurs a new mosaic state
is selected at random among all possible states.
We let T(Sj)5T(xj)1T(yj) denote the genotype implied
by state Sj and define the emission probabilities P(Gj|Sj) as
a function of the error parameter ej:
PðGjjSjÞ ¼
ð1ejÞ21e2j ; TðSjÞ¼Gj and Gj is heterozygote;
2ð1ejÞej; TðSjÞ6¼Gj and Gj is heterozygote;
ð1ejÞ2; TðSjÞ¼Gj and Gj is homozygote;
ð1ejÞe; TðSjÞ is heterozygote and
Gj homozygote;
e2j ; TðSjÞ and Gj are opposite
homozygotes:
8>>>><
>>>>>:
Initially, we let set yj5 y5 0.01 and ej5 e5 0.01 or some
other suitable constant. As we sample a new mosaic state
for each individual we keep track of the number and
location of change points in the mosaic and of the number
of times that the genotype implied by the sampled mosaic
state matches the observed genotype (or not). These
quantities are then used to update the yj and ej parameters
for the next iteration. It is important to avoid setting either
yj5 0 or ej5 0, as that could make it difficult for our
Markov sampler to investigate different mosaic config-
urations. To avoid this, a combined crossover parameter is
estimated for intervals with a small number of sampled
changes in mosaic state and an analogous procedure is
employed for markers with a small number of observed
mismatches between the mosaic and observed genotypes.
Overall, we expect the yj will reflect a combination
of population recombination rates and the relatedness
between the haplotypes being resolved and the true
underlying haplotypes (for example, if CEU chromosomes
are used as templates to resolve CHB genotypes we expect,
on average, higher y estimates than when other CHB
individuals are used as templates). We considered using
distance between flanking markers to inform estimates of
yj (since y’s are generally larger in larger intervals), but did
not find noticeable improvements. Overall, we expect that
ej will reflect a combination of genotyping error, gene
conversion events, recurrent mutation and, when geno-
type data from multiple platforms or laboratories is used,
assay inconsistencies between different platforms. We
observed slightly lower data quality measures (completeness,
832 Li et al.
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duplicate concordance, Hardy–Weinberg test statistics) for
markers with large estimates of ej in the FUSION GWAS.
GENOTYPE IMPUTATION AND ESTIMATES OF
IMPUTATION QUALITY
Genotype imputation analyses proceed similarly to the
haplotyping analyses described above, but do not require
each sampled haplotype configuration to be stored.
Instead, after each iteration, a series of counters is updated
to indicate the number of times each genotype was
sampled at a particular position. Once all iterations are
completed, these counters give an indication of the relative
probability of observing each possible genotype and can
be used to impute the most likely genotype and to
calculate various measures of the quality of imputed
genotypes.
Without loss of generality, consider a SNP with alleles A
and B. Let nA/A, nA/B, and nB/B be the number of times
each possible genotype was sampled after I5 nA/A1
nA/B1nB/B iterations. For downstream analysis of imputed
alleles, we typically consider either the most likely
genotype or the expected number of copies of allele A.
The most likely genotype is simply the genotype that was
sampled most frequently. The expected number of counts
of allele A is the genotype score g5 (2nA/A1nA/B)/I. Both
of these quantities can be conveniently incorporated into a
variety of analysis, including regression-based association
analysis of discrete or quantitative traits.
To measure the accuracy of imputation for a single
imputed genotype IG, we define the genotype quality
score Q5 nIG/I. This quantity can be averaged over all
genotypes for a particular marker to quantify the average
accuracy of imputation for that marker. We have found
that a better measure of imputation quality for a marker is
the estimated r2 between true allele counts and estimated
allele counts (Fig. 1). This quantity can be estimated by
comparing the variance of the estimated genotype scores
with what would be expected if genotype scores were
observed without error. For a given SNP, let Var(g) be the
variance of estimated genotype and let p5Mean(g)/2 be
the estimated frequency of allele A. The estimated r2 with
true genotypes can then be defined as
Eðr2 with true genotypesÞ ¼ VarðgÞ=½2pð1 pÞ:
An alternative definition is
Eðr2 with true genotypesÞ
¼ VarðgÞ=ðð4nA=A1nA=BÞ=I  ½ð2nA=A1nA=BÞ=I2Þ:
Empirically, we have found that while both definitions
lead to similar conclusions, the first definition appears to
be marginally better.
ASSOCIATION ANALYSIS USING IMPUTED
GENOTYPES
When analyzing the FUSION data [Scott et al., 2007], we
included imputed genotype scores as predictors in a
logistic regression that also included age, sex, and
geographic origin as covariates. For analyzing simulated
case-control data, we simply used a t-test to compare the
average genotype scores in cases and controls. Other
approaches to the analysis of imputed data are possible
but, in our experience, the imputed genotype scores
provide a good balance between computationally demand-
ing multiple imputation procedures [Servin and Stephens,
2007] and analyses that simply use the most likely
genotype.
HMM FOR SHOTGUN SEQUENCE DATA
(SIMULATIONS)
When shotgun re-sequencing, or another single mole-
cule re-sequencing technology, is used on diploid indivi-
duals, genotypes are not directly observed. In this case, we
assume the data consists of counts Aj and Bj indicating
how many times base A (or B) was observed at site j. We
then define our HMM as
PðA;B;SÞ¼PðS1Þ
YL
j¼2
PðSjjSj1Þ
YL
j¼1
X
Gj
PðGjjSjÞPðAj;BjjGjÞ
8<
:
9=
;:
Here, we sum over possible genotypes at each site and
calculate the probability of the observed traits for each
possible genotype set. In addition, we define the prob-
ability of observing a specific set of traces given the
underlying genotype as
PðAj;BjjGjÞ ¼
BinomialðAj;Aj1Bj; 1 dÞ; Gj ¼ A=A;
BinomialðAj;Aj1Bj; 0:5Þ; Gj ¼ A=B;
BinomialðAj;Aj1Bj; dÞ; Gj ¼ B=B:
8<
:
The parameter d denotes the per base sequencing error
rate and can be separated from the effects of mutation and
gene conversion captured in e, unless the re-sequencing
depth is very low.
In principle, the method could be applied to all sites
where an alternative base call is observed at least once.
However, since we simulated many short reads and an
error rate of 0.2%, the minor allele was observed at least
once at nearly every simulated position. For reasons of
computational efficiency, we applied the MaCH 1.0
haplotyper only to positions were the minor allele was
observed multiple times. Specifically, we definedmkj as the
number of traces where the minor allele was observed at
position j in individual k. Then, we defined the score wj ¼P
k mkjðmkj11Þ=2 and applied our haplotyping algorithm to
all sites where wj exceeded a predefined threshold (other
sites were assumed to contain the major allele). The score
gives higher weight to sites where the minor allele is
observed multiple times in the same individual. We used
thresholds for wj of 5, 7, 9, 11, 13 depending on whether the
total coverage (defined as depth individuals) was 200,
400, 800, 1,200, or 1,600 . When the number of indivi-
duals sequenced was 400, these thresholds were reduced
to 4, 6, 8, 10, and 12, respectively. This means that, for
example, when 400 individuals were re-sequenced at 4
depth (total depth5 1,600 ) we considered only sites
where the minor allele was observed in at least 12 traces
from different individuals or slightly fewer traces con-
centrated in one or more individuals.
HMM FOR SHOTGUN SEQUENCE DATA
(SIMULATIONS)
The model described above is convenient for the
analysis of simulated data where the per base error rate
is constant. For analyses of real data, where base quality
scores are associated with individual bases, we adapted
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our implementation to use P(base calls, quality scores|G) as
stored in Genotype Likelihood Files generated by samtools
[Li et al., 2008, 2009a].
COMPUTATIONAL EFFICIENCY
A number of optimizations are possible to increase the
computational efficiency of our model. For example, since
haplotype states are unordered only H(H11)/2 distinct
states must be considered at each location, rather than H2
distinct states. Below, we summarize some of the other
efficiencies that we identified and how these are im-
plemented in MaCH.
TRANSITION MATRICES
When sampling a mosaic state S conditional on the
observed genotypes G, we rely on the Baum algorithm.
The algorithm requires a series left and right conditioned
probability vectors which provide an indication of the
relative probability of a specific state at a given location
conditional observed genotypes at markers to its left (or
right). For example, the probability of observing state (x,y)
at location j conditional on all preceding genotypes is
simply:
LeftðSj ¼ ðx; yÞÞ ¼ LðSj ¼ ðx; yÞjG1;G2; . . . ;Gj1Þ
¼
X
ða;bÞ
LeftðSj1 ¼ ða; bÞÞPðSj ¼ ðx; yÞjSj1
¼ ða; bÞÞPðGj1jSj1 ¼ ða; bÞÞ;
LeftðS1 ¼ iÞ ¼ 1:
The calculation of these probabilities can be sped up by
taking advantage of the regular patterns in the transition
matrices. Specifically, we define the quantities:
CðaÞ ¼
X
b
LeftðSj1 ¼ ða; bÞÞPðGj1jSj1 ¼ ða; bÞÞ;
C ¼
X
a
CðaÞ:
Then, the previous definition becomes:
LeftðSj ¼ ðx; yÞÞ
¼ LeftðSj1 ¼ ðx; yÞÞPðGj1jSj1 ¼ ðx; yÞÞð1 yjÞ2
1CðxÞð1 yjÞyj=H1CðyÞð1 yjÞyj=H1Cy2j =H2;
LeftðS1 ¼ iÞ ¼ 1:
When this updated definition is used to calculate left
conditional probabilities for each possible state, computa-
tional requirements become O(H2) rather than O(H4) using
the original definition, provided that C(a) and C are pre-
computed. An analogous speed up is available for right-
conditioned probabilities.
MEMORY EFFICIENCY
One large computational constraint when applying our
algorithm on a genomic scale is the storage required to
track left-conditioned probabilities. Typically, this requires
storage of L vectors each with H2 elements (or, as noted
above H(H11)/2 elements). It is clear that this requirement
becomes cumbersome as the number of polymorphic sites
increases. We devised a solution that requires storage of
only 2sqrt(L) vectors. For notational convenience let
K5 sqrt(L). Our algorithm pre-allocates 2K vectors and
organizes these into two groups: a framework set of K
vectors, and a working set of another K vectors. When left-
conditional probabilities are first calculated, proceeding
left to right, we store every Kth vector in the framework set
and discard other intermediate results. Then, as these
vectors are used in the second pass of the chain (which
combines left and right conditional probabilities, proceed-
ing right to left), we recalculate K of these vectors at a time
(starting from the nearest vector in the framework set) and
store them in the working set of vectors. Completing the
full chain requires calculation of all L vectors of left
conditional probabilities, recalculation of K of these vectors
L/K times, and calculation of L vectors of right conditional
probabilities. Overall, our solution no more than doubles
computing time (since each vector of left conditional
probabilities must be calculated twice), but reduces
memory requirements from O(L) to O(L1/2). The solution
is general and can be applied to many other HMMs (see
also [Wheeler and Hughey, 2000]).
REDUCING THE NUMBER OF TEMPLATES
If all available chromosomes are used as templates, the
complexity of our algorithm will increase cubically with
sample size (because the cost of each update increases
quadratically and the number of updates increases linearly
with sample size). One way to avoid this is to restrict the
size of the template pool. When there are more than a pre-
specified number of potential templates (say H4300), we
typically select a random subset of these for each update.
With this restriction, the complexity of our algorithm
increases only linearly with sample size (because the cost
of each update now remains fixed and only the number of
updates to be performed grows). Furthermore, even
though each update is based on only a random sample
of the available haplotypes, the overall quality of solutions
still increases with sample size. When the focus is on
genotype imputation, rather than haplotyping, an alter-
native is to use as templates individuals who have been
genotyped for the markers being imputed (e.g. the
HapMap reference samples). Both of the above solutions
are heuristics that trade-off some accuracy for computa-
tional efficiency. An alternative strategy for reducing the
size of the template pool is to consider local similarities
and redundancies among the haplotypes in the pool. These
redundancies are already exploited to increase computa-
tional efficiency in the handling of other Markov models
[Abecasis et al., 2002; Markianos et al., 2001], and our
preliminary implementations suggest that speed-ups of
5–10 are possible for our haplotyping model.
834 Li et al.
Genet. Epidemiol.
